Euroasian Journal of Hepato-Gastroenterology

Register      Login

VOLUME 5 , ISSUE 2 ( July-December, 2015 ) > List of Articles

CASE REPORT

Hepatitis B Virus Reactivation under Treatment with Nilotinib

Tuncer Temel, Eren Gunduz, Esmira Sadigova, Hava Uskudar Teke, Safak Meric Ozgenel, Aysegul Harmanci Ozakyol

Citation Information : Temel T, Gunduz E, Sadigova E, Uskudar Teke H, Meric Ozgenel S, Harmanci Ozakyol A. Hepatitis B Virus Reactivation under Treatment with Nilotinib. Euroasian J Hepatogastroenterol 2015; 5 (2):112-114.

DOI: 10.5005/jp-journals-10018-1147

License: CC BY-NC 4.0

Published Online: 01-07-2015


Abstract

Hepatitis B virus (HBV) reactivation with imatinib, a tyrosine kinase inhibitor, has been reported in chronic myeloid leukemia. Nilotinib is a more potent second generation tyrosine kinase inhibitor and it inhibits the Src-family kinase LCK and hamper proliferation and function of CD8 (+) T lymphocytes. CD8 (+) T lymphocytes are the main cellular subset responsible for viral clearance in patients with HBV infection. We report a case of HBV reactivation under treatment with nilotinib. Fatal HBV reactivation is not usually related to death in chronic myeloid leukemia patients who have an expectation of longevity with well-tolerated oral drugs. Thus, screening for latent chronic HBV infections including assessment of hepatitis B surface antigen (HBsAg), antibody to hepatitis B core antigen (anti-HBc antibody) and antibody to hepatitis B surface antigen (anti-HBs), especially at countries with intermediate and high prevalence of HBsAg is warranted. Treatment with nucleoside analogs and close monitoring may be life-saving in this context.


PDF Share
  1. Schilsky ML. Hepatitis B ‘360’. Transplant Proc 2013;45(3): 982-985
  2. Burden of pediatric hepatitis. World J Gastroenterol 2013;19(44):7880-7888
  3. Immunosuppression and HBV reactivation. Semin Liver Dis 2013;33(2):167-177
  4. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol 2013;169(6):1295-1303
  5. Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor. World J Gastroenterol 2013;19(8):1318-1321
  6. Reactivation of chronic hepatitis B infection related to imatinibmesylate therapy in patients with chronic myeloid leukemia: two cases report and literatures review. Zhonghua Xue Ye Xue Za Zhi 2012;33(9):743-746. (Article in Chinese) 7. Wang YD, Cui GH, Li M, Gowrea B, Xia J, Hu Y. Hepatitis B virus reactivation in a chronic myeloid leukemia patient treated with imatinib mesylate. Chin Med J 2012;125(14): 2636-2637
  7. Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports. Transplant Proc 2010;42(3):843-835
  8. Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review. Int J Hematol 2009;90(3):383-337
  9. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma 2006;47(1):155-157
  10. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62(3):299-307
  11. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004;90(7):1306-1311
  12. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy pathogenesis and management. Rev Med Virol 2001;11(5): 287-299
  13. Management of viral hepatitis in hematologic malignancies. Blood Rev 2008;22(3):117-126
  14. Advances in the biology and therapy of patients with chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009;22(3):395-407
  15. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005;105(6):2473-2479
  16. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004;18(8):1332-1339
  17. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 1999;17(1):394-398
  18. Imatinib-induced fatal acute liver failure. World J Gastroenterol 2007;13(48):6608-6611
  19. AASLD clinical practice guidelines: chronic hepatitis B. Hepatol 2009; 50(3):1-38
  20. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57(1):167-185
  21. American Gastroenterological Association Institute. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterol 2015;148(1):215-219
  22. The immune response during hepatitis B virus infection. J Gen Virol 2006;87(pt6):1439-1449.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.